Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Clinical trial NCT05514444 · COMPLETED
Trial details
- NCT number
- NCT05514444
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-25
- Primary completion
- 2025-09-18
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.